Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
Eli Lilly Japan and Mitsubishi Tanabe Pharma have expanded their shipment control to all versions of their type 2 diabetes treatment Mounjaro (tirzepatide), with two dosage forms newly added to their restriction list from August 7. “We have decided on…
To read the full story
Related Article
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
- Novo’s Koriyama Plant Achieves Net-Zero CO2 Emissions
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…